Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05853783
Other study ID # PRO-STR-PPOEL-2
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2023
Est. completion date December 2024

Study information

Verified date April 2024
Source Proteocyte Diagnostics Inc.
Contact Jody Filkowski, BSc, MSc, PhD
Phone 1-825-305-0749
Email Jody.Filkowski@medlior.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective cohort of patients who received biopsies.


Description:

The study objectives are to: 1. Evaluate STRATICYTE™ sensitivity and specificity in a cohort of patients that meet the inclusion/exclusion criteria. 2. Identify patient and clinical characteristics influencing the sensitivity and specificity of the STRATICYTE™ model. 3. Estimate the correlation between STRATICYTE™ outcome and time to a positive diagnosis of oral cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date December 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - From the archive, any patient who presents with clinically evident oral lesions and biopsy-proven dysplasia (punch or scalpel biopsies; any grade or classification system) - Patients with initial oral lesions with epithelial atypia suspicious for neoplasia, with: - No histological evidence of cancer with clinical follow-up data for a period of at least five years; or - OSCC development (histologic or documented evidence of invasive cancer). - Patients who had archived biopsy tissue blocks of a previous oral lesion(s) meeting the above criteria and retained at the same clinical center. Exclusion Criteria: - Patients with oral lesions or dysplasia with no indication of OSCC development or follow-up data of less than five years in non-OSCC patients. - Patients diagnosed with oral epithelial dysplasia concomitant with OSCC at the time of the biopsy's original pathology report or a subsequent clinical note of cancer progression within three months post-biopsy.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
STRATICYTE™ Test
Assessment for risk of progression to oral cancer

Locations

Country Name City State
United States The University of Alabama at Birmingham Birmingham Alabama
United States MD Anderson Cancer Cetner Houston Texas
United States UTHealth Houston School of Dentistry Houston Texas
United States Loma Linda University Loma Linda California
United States Minnesota Oral and Facial Surgery Minneapolis Minnesota

Sponsors (5)

Lead Sponsor Collaborator
Proteocyte Diagnostics Inc. Loma Linda University, Minnesota Oral & Facial Surgery, The University of Texas Health Science Center, Houston, University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

References & Publications (5)

Hwang JT, Gu YR, Shen M, Ralhan R, Walfish PG, Pritzker KP, Mock D. Individualized five-year risk assessment for oral premalignant lesion progression to cancer. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Mar;123(3):374-381. doi: 10.1016/j.oooo.2016.11.004. Epub 2016 Nov 22. — View Citation

Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I, Witterick I, Colgan TJ, Macmillan C, Siu KW, Walfish PG, Ralhan R. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. Int J Cancer. 2014 Mar 15;134(6):1379-88. doi: 10.1002/ijc.28473. Epub 2013 Oct 8. — View Citation

Ralhan R, Desouza LV, Matta A, Tripathi SC, Ghanny S, Datta Gupta S, Bahadur S, Siu KW. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics. 2008 Jun;7(6):1162-73. doi: 10.1074/mcp.M700500-MCP200. Epub 2008 Mar 13. — View Citation

Ralhan R, Desouza LV, Matta A, Tripathi SC, Ghanny S, Dattagupta S, Thakar A, Chauhan SS, Siu KW. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res. 2009 Jan;8(1):300-9. doi: 10.1021/pr800501j. — View Citation

Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R, Siu KW. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One. 2010 Aug 3;5(8):e11939. doi: 10.1371/journal.pone.0011939. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity and Specificity Standard measures of accuracy calculated using cross-tabulation of predicted risk category and confirmed cancer progression over a 5-year period from biopsy 5 years
Primary Survival analysis Kaplan-Meier analyses to compare time to a positive diagnosis of oral cancer between patients/biopsies with a STRATICYTE™ classification of Low- and Elevated-Risk. 5 years
Secondary AUC Area under the receiver operator curve 5 years
Secondary C-index (Harrell's) From all possible pairs of patients, compute the number of concordant and discordant pairs. Compute C-index as the proportion of all possible pairs that are concordant. 5 years
See also
  Status Clinical Trial Phase
Completed NCT02913235 - Salivary Bacterial Associations to Short Term Discontinuation of Self-performed Oral Hygiene N/A
Terminated NCT02374905 - Testing Interventions to Reduce Alcohol Consumption Among Outpatients in a Dental Setting N/A
Completed NCT04074395 - Oral and Maxillofacial Pathology in Pediatric Patients
Completed NCT01902095 - Clinical Effects of Tooth Powder on Gingivitis Phase 2
Completed NCT05787600 - Anti-inflammatory and Anti-plaque Efficacies of Mouth Rinse Containing Hyaluronic Acid and Hydrogen Peroxide Phase 3
Completed NCT02774967 - Comparation Between Two Surgical Techniques With Acellular Dermal Matrix in Treatment of Gingival Recessions N/A
Completed NCT05435131 - Evaluation of Biomarkers Levels in Gingival Crevicular Fluid, Saliva and Serum for Different Periodontal Diseases N/A
Completed NCT02357199 - Interventional Study Targeting Oral Infections in Patients With Chronic Kidney Disease N/A
Completed NCT02894372 - Faringomoss Effectiveness in Inhibiting Acute Throat Pain and Discomfort N/A
Completed NCT02870270 - Prospective Studies on Oral Health and Quality of Life in Head and Neck Cancer Patients N/A
Completed NCT00230191 - Safety and Efficacy of RK0202 in Oral Mucositis Phase 2
Completed NCT02500654 - Regenerative Surgical Treatment of Peri-implantitis Phase 4
Completed NCT04273386 - Mouth Handicap in Systemic Sclerosis N/A
Recruiting NCT02737176 - Tobacco Cessation Intervention Study for Oral Diseases N/A
Completed NCT01915966 - Efficacy Study of a Ginger and Cardamom Gelatin for Xerostomy in Terminally Ill Patients N/A
Completed NCT00444977 - Enhancing Oral Health Care Use by HIV Positive Individuals N/A
Recruiting NCT00540774 - Optical Sensor for Photodynamic Detection of Oral Pathology N/A
Active, not recruiting NCT00000111 - Intraoral Grafting of Ex Vivo Produced Oral Mucosal Composites Phase 1